The First-Line Frontier: What Amgen's Imdelltra Phase 3 Win Means for Small Cell Lung Cancer

Small cell lung cancer has long occupied a uniquely grim position in oncology. It is fast, it is aggressive, and it has resisted meaningful improvement for decades. The median survival from the start of first-line maintenance treatment has hovered around one year. Only about 40 percent of patients with extensive-stage disease ever reach second-line therapy. For most, the window between diagnosis and death is measured in months, not years.

On September 8, 2026, Amgen announced that the Phase 3 DeLLphi-305 trial had met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival with Imdelltra (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi (durvalumab) compared to durvalumab alone as first-line maintenance treatment for extensive-stage small cell lung cancer. The study also met secondary endpoints for progression-free survival and objective response rate. No new safety signals were identified.

The result is not just a commercial milestone for Amgen. It is the first time a Phase 3 trial of a bispecific T-cell engager has demonstrated an overall survival benefit in the first-line maintenance setting for this disease. That distinction matters more than it might initially appear.

What Tarlatamab Does, and Why It Works Here

Tarlatamab is a bispecific T-cell engager, a class of engineered antibodies designed to simultaneously bind two different targets and physically bring them together. In this case, the drug binds DLL3 on tumor cells and CD3 on T cells, forming a cytolytic synapse that activates the immune system to kill the cancer. DLL3 is expressed on the surface of SCLC cells in approximately 85 to 96 percent of patients, but is minimally expressed on healthy tissue, making it a precise and attractive target.

The drug received accelerated FDA approval in May 2024 for previously treated extensive-stage SCLC, based on Phase 2 data showing a 40 percent objective response rate. The DeLLphi-304 Phase 3 trial subsequently converted that accelerated approval to a full one, based on an overall survival win in the second-line setting. DeLLphi-305 now extends that story into the first-line maintenance setting, where the patient population is larger and the potential impact on the natural history of the disease is considerably greater.

The Phase 1b DeLLphi-303 trial had already provided a compelling preview. Extended follow-up data published in The Lancet Oncology showed a median overall survival of 25.3 months in patients receiving tarlatamab plus anti-PD-L1 therapy as first-line maintenance, compared to the 10.6 to 13.2 months historically achieved with standard maintenance approaches. That signal was striking enough to generate serious attention, and DeLLphi-305 was designed to confirm it in a randomized, controlled setting. The trial enrolled 563 patients, randomized 1:1 to receive either tarlatamab plus durvalumab or durvalumab alone following initial treatment with durvalumab, platinum-based chemotherapy, and etoposide.

Why the Timing of This Win Matters

The significance of moving tarlatamab into the first-line maintenance setting is not simply about earlier access to an effective drug. It is about reaching the patients who would otherwise never benefit from it at all. Because only 40 percent of extensive-stage SCLC patients reach second-line therapy, a drug that is only available after first-line failure is structurally limited in how many lives it can affect. A first-line maintenance approval changes that arithmetic entirely.

Jacob Sands, MD, of Dana-Farber Cancer Institute, who served as an investigator on the trial, described the DeLLphi-305 results as among the most compelling survival data he had seen in a career treating this disease, suggesting the field may be entering a new era where meaningfully longer survival is possible for more patients. That framing is not hyperbole. It reflects a genuine shift in what the treatment paradigm for extensive-stage SCLC might look like if these data translate into regulatory approval and clinical adoption.

Amgen has said it will present detailed data at an upcoming international medical congress and share the results with regulatory authorities. The path to a supplemental approval for the first-line maintenance indication is now clearly in view, and the competitive landscape will need to reckon with what a tarlatamab-based maintenance regimen means for every other program in the space.

The Broader Implications for the DLL3 Field

The DeLLphi-305 result arrives at a moment when the DLL3 target has attracted significant competitive interest. Merck has been developing a DLL3 bispecific in combination with a B7-H3-directed antibody-drug conjugate. Roche obtained a DLL3 ADC from Innovent Biologics. AbbVie acquired a DLL3-directed trispecific T-cell binder. Novartis has partnered with Legend Biotech on a DLL3 autologous CAR-T program. Boehringer Ingelheim has advanced its own DLL3 T-cell engager into Phase 3 testing.

The validation that DLL3 targeting can produce an overall survival benefit in the first-line setting strengthens the scientific rationale for all of these programs, while simultaneously raising the bar that any competitor will need to clear. Tarlatamab now has two Phase 3 OS wins in SCLC, a first-line maintenance approval pathway in sight, and a clinical trial program that spans limited-stage disease, subcutaneous formulations, and combination strategies with other novel agents. The competitive moat around the DLL3 target, at least in SCLC, is deepening.

What This Means for Patients

Small cell lung cancer kills approximately 250,000 people globally each year. The disease has been defined, for most of its clinical history, by the speed with which it defeats treatment. The arrival of immunotherapy combinations improved outcomes modestly. The approval of tarlatamab in the second-line setting improved them further. A first-line maintenance approval, if it follows from the DeLLphi-305 data, would represent the most significant shift in the treatment paradigm for this disease in a generation.

The detailed data have not yet been presented, and the regulatory process will take time. But the topline result from DeLLphi-305 is the kind of signal that changes how oncologists think about what is possible in a disease that has resisted progress for so long. For patients with extensive-stage small cell lung cancer, the question has always been whether the science could move fast enough to matter. The DeLLphi-305 result suggests it finally has.